Clinical Experience: Leading the Way

CUROSURF® (poractant alfa) continues to lead the way for rescue treatment of respiratory distress syndrome in premature infants.1,2* Review the data to see how high-sustained market share makes CUROSURF the market leader for NICUs across the country and globe.2-4


CUROSURF: The #1 most used surfactant in the US and worldwide2,4*†


With decades of clinical use, CUROSURF remains an established option for the rescue treatment of RDS in premature infants.1,5 This commitment is supported by 30+ years of worldwide clinical use, adoption in more than 90 countries globally, and a legacy that includes 8+ million treated infants.5

World map with 3 circles which read: 30+ years of worldwide clinical experience; used in 90+ countries worldwide; 8 million infants treated.
#1 Most Used Surfactant in the US seal with reference cue and asterisk to footnote

In the US, CUROSURF is chosen by the majority of hospitals that use surfactant.2

*Most used surfactant worldwide among US FDA-approved surfactants. Number of countries where used varies for each surfactant. CUROSURF is available in more than 90 countries; Infasurf is available in 30 countries; these global data for Survanta are not available.4-6

†Please note that this metric only provides insight into the surfactant selected by NICUs in the US and does not imply equivalence or superiority between or among the products for any given clinical endpoint.

Leading the way in global market share among US FDA-approved surfactants4*

Its global scale has positioned CUROSURF as the most-used surfactant therapy worldwide, with a 94% market share among US FDA-approved surfactants.

Bar graph of US FDA-approved surfactants’ global market share. CUROSURF (poractant alfa): 94%, Survanta (beractant): 5%, and Infasurf (calfactant): 1%.

Chosen by the majority of top US hospitals that use surfactant2

See the data: CUROSURF is the surfactant most widely used by institutions across the US.

Share of hospitals (%) based on total volume administered

96%

share of

Top 10 Children’s Hospitals2,7‡

US News and World Report

91%

share of

US Member Hospitals2,8§

Children’s Hospital Association

93%

share of

Vermont Oxford Network2,9¶

Member Hospitals

‡Based on US News and World Report’s “Best Children’s Hospitals Honor Roll 2025-2026.”

§Based on any surfactant use or purchases reported by member hospitals listed in the Children’s Hospital Association’s “Children’s Hospital Directory.”

Based on Vermont Oxford Network member hospitals.

US News and World Report: 50 Best Hospitals for Neonatology#

Bar graph of 50 best hospitals for neonatology and their chosen surfactant - see image description

#Based on US News and World Report’s 2025-2026 “50 Best Hospitals for Neonatology.” Some hospitals may choose multiple surfactants; therefore, they may be counted more than once in the data for each surfactant.

Widely used by fellowship programs and large teaching hospitals3,11

89%

of the fellowship programs in the US select CUROSURF||

95%

CUROSURF accounts for >90% surfactant use in 95% of teaching hospitals‖

CUROSURF use has grown since 200912

400%

account growth

5X

the accounts

‖“89% of the fellowship programs” is calculated based on mL volume, and “95% of teaching hospitals” is calculated based on the number of hospitals using ≥100 mL annually.

Most NICUs returned to CUROSURF after trying a different surfactant**

Among NICUs that started with CUROSURF and trialed a different product later, 91% returned to CUROSURF, affirming its market position.

US NICUs that returned after 6, 12, and 24 months

Most NICUs returned graph - see image description.

**The number of hospitals returning to CUROSURF after trying a different surfactant is calculated by dividing the number of accounts recovered at each time point by the total number of accounts. The reason for returning to CUROSURF is unknown. Data showing values for accounts up to 24 months prior was accessed in February 2019.

Chosen by more US NICUs than all other surfactants combined2,3

Since 2003, CUROSURF use has steadily grown—it’s now chosen more frequently than all other surfactants combined.

The most used surfactant for 15 years and counting††

More NICUs select CUROSURF® (poractant alfa) graphic - see image description

††The number of patients treated with each surfactant is calculated by dividing the total amount of each surfactant sold by the average amount of surfactant each patient receives. Please note that this metric only provides insight into the surfactant selected by NICUs and does not imply equivalence or superiority between or among the products for any given clinical end point.

‡‡Number shown is not indicative of full market share for 2025 and is actually a rolling market share from October 2024-September 2025.

§§CUROSURF is FDA-approved for an initial dose of 200 mg/kg (2.5 mL/kg). The 100 mg/kg (1.25 mL/kg) dose of CUROSURF is approved for repeat dosing only.

Want more information about CUROSURF and RDS in premature infants?

Gain quick access to multiple clinical studies and other resources all in one integrated library.


IMPORTANT SAFETY INFORMATION

CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

INDICATION

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Please see Full Prescribing Information.

References: 1. CUROSURF® (poractant alfa) Intratracheal Suspension Prescribing Information, Chiesi USA, Inc. May 2021. 2. IQVIA Drug Distribution Data, Total Year Q2 2025. 3. IQVIA SMART-US Edition, National Sales Perspectives, All Channels September 2020. 4. IQVIA Global Market Share. Total Year Q2 2025. 5. Data on file, Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc. 6. ONY Biotech website. Accessed January 22, 2025. https://onybiotech.com/products/infasurf 7. US News and World Report Best Children’s Hospitals. Accessed November 14, 2025. https://health.usnews.com/best-hospitals/pediatric-rankings 8. Children’s Hospital Association website. Accessed December 14, 2025. https://www.childrenshospitals.org/hospital-directory. 9. Vermont Oxford Network website. Accessed December 14, 2025. https://public.vtoxford.org/member-map/ 10. US News and World Report Best Hospital for Neonatology. Accessed November 20, 2025. https://health.usnews.com/best-hospitals/pediatric-rankings/neonatal-care 11. Neonatology Fellowship Programs—Neonatology Solutions. Accessed December 24, 2025. 12. Data on file, Chiesi USA, Inc. 13. Survanta (beractant) Intratracheal Suspension Prescribing Information, AbbVie Inc. October 2020. 14. Infasurf (calfactant) Intratracheal Suspension Prescribing Information, ONY, Inc. August 2024. 15. Taeusch HW, Lu K, Ramierez-Schrampp D. Acta Pharmacol Sin. 2002;23(suppl):11-15. 16. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group. Am J Perinatol. 2004;21:100-110. 17. Dizdar EA, Sari FN, Aydemir C, Oguz SS, Erdeve O, Uras N, et al. Am J Perinatol. 2012;29:95-100. 18. Gerdes J, Seiberlich W, Sivieri EM, Marsh W, Varner DL, Turck CJ, et al. J Pediatr Pharmacol Ther. 2006;11:92-100. 19. Speer CP, Gefeller O, Groneck P, et al. Arch Dis Child. 1995;72:F8-F13. 20. Collaborative European Multicenter Study Group. Pediatrics. 1988;82:683-691. 21. Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103:1-6. 22. Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Pediatrics. 2004;113:560-565.